Wegovy would cost US government USD 27bn – even with limited uptake
If 10% of Americans insured by Medicare wanted Novo Nordisk’s obesity drug, Wegovy, it would cost around 18.5% of the health program’s total drug spending, a new analysis shows.
By Emma Court, bloomberg
Covering Novo Nordisk A/S’s new obesity drug Wegovy could strain the budget of US government insurance program Medicare, according to a new analysis in the New England Journal of Medicine.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Wegovy exponents did not disclose payments from Novo Nordisk
For subscribers
.jpg&w=384&q=75)
